|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer显示文摘AIM To demonstrate the feasibility of cryopreservation of peripheral blood mononuclear cells(PBMCs) for prognostic circulating tumor cell(CTC) detection in gastroesophageal cancer.METHODS Using 7.5 m L blood samples collected in EDTA tubes from patients with gastroesopheagal adenocarcinoma, CTCs were isolated by epithelial cell adhesion molecule based immunomagnetic capture using the Iso Flux platform. Paired specimens taken during the same blood draw(n = 15) were used to compare number of CTCs isolated from fresh and cryopreserved PBMCs. Blood samples were processed within 24 h to recover the PBMC fraction, with PBMCs used for fresh analysis immediately processed for CTC isolation. Cryopreservation of PBMCs lasted from 2 wk to 25.2 mo(median 14.6 mo). CTCs isolated from pre-treatment cryopreserved PBMCs(n = 43) were examined for associations with clinicopathological variables and survival outcomes.RESULTS While there was a significant trend to a decrease in CTC numbers associated with cryopreserved specimens(mean number of CTCs 34.4 vs 51.5, P = 0.04), this was predominately in samples with a total CTC count of > 50, with low CTC count samples less affected(P = 0.06). There was no significant association between the duration of cryopreservation and number of CTCs. In cryopreserved PBMCs from patient samples prior to treatment, a high CTC count(> 17) was associated with poorer overall survival(OS)(n = 43, HR = 4.4, 95%CI: 1.7-11.7, P = 0.0013). In multivariate analysis, after controlling for sex, age, stage, ECOG performance status, and primary tumor location, a high CTC count remained significantly associated with a poorer OS(HR = 3.7, 95%CI: 1.2-12.4, P = 0.03). CONCLUSION PBMC cryopreservation for delayed CTC isolation is a valid strategy to assist with sample collection, transporting and processing. | Daniel Brungs David Lynch Alison WS Luk Elahe Minaei Marie Ranson Morteza Aghmesheh Kara L Vine Martin Carolan Mouhannad Jaber Paul de Souza Therese M Becker | 2018 | World Journal of Gastroenterology2018，24，7： | 5 |
| 2 | ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors:Results of a phaseⅠ trial 显示文摘 | Ranson M Hammond LA Ferry D | 2002 | J Clin Oncol2002，20，9： | 1 |
| 3 | Application of digital correlation methods to rigid body mechanics显示文摘 | PETERSW H RANSON W F SUTTON M A | 1983 | Optical Engineering1983，22，6： | 1 |
| 4 | Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer显示文摘 | Jayson GC Mulatero C Ranson M | 2005 | Eur J Cancer2005，41，4： | 1 |
| 5 | Phase I safety,pharmacokinetic, and pharmaeodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyroslne kinase inhibitor, in patients with five selected solid tumor types显示文摘 | BASELGA J RISCHIN D RANSON M | 2002 | J Clin Oncol2002，20，21： | 1 |
| 6 | Intermittent oral ZD1839(Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), shows evidence of good tolerability and activity:Final results from a phase I study显示文摘 | Ferry D Hammond L Ranson M | 2000 | Proc Am Soc Clin Oncol2000，19，： | 1 |
| 7 | ZD1839, a selective oral epidermal growth factor receptor- tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial 显示文摘 | Ranson M Hammond L A Ferry D | 2002 | J Clin Onco2002，20，9： | 1 |
| 8 | Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types 显示文摘 | Baselga J Rischin D Ranson M | 2002 | J Clin Onco2002，20，21： | 1 |
| 9 | Applica- tions of Digital-image-correlation Techniques to Ex- perimental Mechanics 显示文摘 | CHU T C RANSON W F SUTTON M A | 1985 | Experimental Mechanics1985，25，3： | 1 |
| 10 | Applications of digitalimage-correlation techniques to experimental mechanics显示文摘 | Chu T C Ranson W F Sutton M A | 1985 | Experimental Mechanics1985，25，3： | 1 |
| 11 | Phase Ⅰ safety pharmacokinetic and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types显示文摘 | Baselga J Rischin D Ranson M | 2002 | J Clin Oncol2002，20，： | 1 |
| 12 | A phase Ⅱ trial with RFS2000 (rubitecan)in patients with advanced non-small cell lung cancer显示文摘 | Baka S Ranson M Lorigan P | 2005 | EurJ Cancer2005，41，11： | 1 |
| 13 | Application of digital image correlation techniques to experimental mechanics显示文摘 | Chu T C Ranson W F Sutton M A | 1985 | Exp Mech1985，25，： | 1 |
| 14 | ZD1839,a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor,is well tolerated and active in patients with solid,malignant tumors:results of a phase I trial 显示文摘 | Ranson M Hammond L A Ferry D | 2002 | J Clin Oncol2002，20，： | 1 |
| 15 | Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer显示文摘 | Jayson GC Mulatero C Ranson M | 2005 | Eur J Cancer2005，41，4： | 1 |
| 16 | ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor,is well tolerated and active in patients with solid, malignant tumors:results of a phase I trial显示文摘 | Ranson M Hammond LA Ferry D | 2002 | J Clin Oncol2002，20，9： | 1 |
| 17 | VAD chemotherapy as remission induction for multiple myeloma显示文摘 | Anderson H Scarffe JH Ranson M | 1995 | Br J Cancer1995，71，2： | 1 |
| 18 | Applications of digital image correlation techniques to experimental mechanics 显示文摘 | Chu T C Ranson W F Sutton M A | 1985 | Experimental Mechanics1985，25，3： | 1 |
| 19 | Application of digital image correlation techniques to experimental mechanics显示文摘 | Chu T C Ranson W F Sutton M A | 1985 | Experimental Mechanics1985，25，： | 1 |
| 20 | X-linked inhibitor of apoptosis protein as a therapeutic target 显示文摘 | Dean EJ Ranson M Blackhall F | 2007 | Expert Opin Ther Targets2007，11，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员